Abstracts

Volume 14Number 2, Part IFebruary, 1986

in younger age groups following cortisone and adre­nocorticotropic hormone. Am J Pathol 28:315-318,1952.

152. Bulkey B, Roberts W: The heart in systemic lupus er­ythematosus and the changes induced in it by cortico­steroid therapy. Am J Med 58:243-264, 1975.

153. Kalbak K: Incidence of atherosclerosis in patients withrheumatoid arthritis receiving long-term corticosteroidtherapy. Ann Rheum Dis 31:196-200, 1972.

154. Buckley B, Robert W: Steroid therapy during acutemyocardial infarction. Am J Med 56:244-249, 1974.

155. Klinenger J, Miller F: Effect of corticosteroids on bloodsalicylate concentration. JAMA 194:131-134, 1965.

156. Chatterjea JB, Salomon L: Antagonistic effect ofA.C.T.H. and cortisone on the anticoagulant activity ofethyl biscoumacetate. Br Med J 2:790-792, 1954.

157. Petereit L, Meikle A: Effectiveness of prednisolone dur­ing phenytoin therapy. Clin Pharmacol Ther 22:913­916, 1977.

158. Pickup M: Clinical phannacokinetics of prednisone andprednisolone. Clin Pharmacokinet 4:111-128, 1979.

159. Melby J: Systemic corticosteroid therapy, pharmacologyand endocrinologic considerations. Ann Intern Med81:505-512, 1974.

160. Olefsky J, Kimmerling G: Effects of glucocorticoids oncarbohydrate metabolism. Am J Med Sci 271:202-210,1976.

161. Dumler F, Hayashi H, Hunter J, et al: Racial differences

Oral glucocorticoids 177

in the incidence of steroid diabetes in renal transplantpatients. Henry Ford Hosp Med J 30: 14-16, 1982.

162. Blereau R, Weingarten C: Diabetic acidosis secondaryto steroid therapy. N Engl J Med 271:836, 1964.

163. Boyer M: Hyperosmolar anacidotic coma in associationwith glucocorticoid therapy. lAMA 202:1007-1009,1967.

164. Pennisi A, Fiedler J, Lipsey A, et al: Hyperlipidemiain pediatric renal allograft recipients. J Pediatr 87:249-251, 1975.

165. EI-Shaboury A, Hayes T: Hyperlipidemia in asthmaticpatients receiving long-term steroid therapy. Br Med J2:85-86, 1973.

166. Brennan M: Corticosteroids in the treatment of solidtumors. Med Clin North Am 57:1225-1240, 1973.

167. Starzl TE, Penn I, Putnam CW, et al: Iatrogenic altcr­ations of immunologic surveillance in man and theirinfluence on malignancy. Transplant Res 7: 112-145,1971.

168. Sherlock P: Adrenal cortical steroids in the pattcrns ofmetastases. lAMA 181:313-315, 1962.

169. Hoshaw R, Schwartz R: Kaposi's sarcoma after im­munosuppressive therapy with prednisone. Arch Der­matoI116:1280-1282, 1980.

170. Leung F, Fam A, Osoba D: Kaposi's sarcoma compli­cating cortical steroid therapy for temporal arteritis. AmJ Med 71:320-322, 1982.

ABSTRACTS

Lipedema (German text)

Stenger D, Bahmer FA: Akt Dermatol11:51-54,1985

Lipedema, manifested by symmetric swelling of the legs,is not well known. The term is misleading, since it is path­ogenetically not an edema but a constitutional disturbance offat distribution. Young women are mostly affected. Fiftypercent of the patients are obese; in another 50% only thelower extremities are obese. Treatment is very unsatisfactory.Phlebedema and lymphedema are to be considered in thedifferential diagnosis.

Alfred Hollander, M.D.

Basal cell nevus syndrome and radiation therapy(German text)

Roth C, Breuninger H, Rassner G: Akt Dermatol11:55-57, 1985

In a 32-year-old man with basal cell nevus syndrome,x-ray therapy (10,000 rads) was administered to eight tumorson the trunk that had previously been excised. Subsequentlynevoid basal cell carcinomas developed in the irradiated areas.X-ray therapy is contraindicated in basal cell nevus syndrome.Intensive ultraviolet therapy may also be a risk.

Alfred Hollander, M.D.

Lichen follicularis decalvans, spinulosus etpigmentosus (German text)

Stadtler R, Schaumburg-Lever G: Akt Dermatol11 :58-63, 1985

A 36-year-old patient with Graham-Little syndrome alsoshowed manifestations of erythema dyschromicum perstanson the trunk. Authors are not certain whether this case rep­resents a variant of Graham-Little syndrome or a simultaneousappearance of Graham-Little· syndrome or erythema dys­chromicum perstans. Pathogenetically, toxic influences ofmedicaments were considered since ash-gray pigmentationsappeared and disappeared repeatedly.

Alfred Hollander, M.D.

Association of HLA antigens with scleroderma(German text)

KUhnl P, Schlitz K, Altmeyer P, et al: Z Hautkr60:866-868, 1985

Progressive systemic and circumscribed scleroderma areassociated with different HLA antigens, DRl, DRS, and B27,respectively. HLA typing in suspected cases of progressivesystemic scleroderma can be useful in securing the diagnosis.

Alfred Hollander, M.D.